Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cyclerion Therapeutics (CYCN) Non Operating Income (2020 - 2025)

Cyclerion Therapeutics has reported Non Operating Income over the past 6 years, most recently at $30000.0 for Q3 2025.

  • Quarterly results put Non Operating Income at $30000.0 for Q3 2025, down 92.59% from a year ago — trailing twelve months through Sep 2025 was $1.4 million (up 122.67% YoY), and the annual figure for FY2024 was $571000.0, up 59.5%.
  • Non Operating Income for Q3 2025 was $30000.0 at Cyclerion Therapeutics, down from $1.3 million in the prior quarter.
  • Over the last five years, Non Operating Income for CYCN hit a ceiling of $1.3 million in Q2 2025 and a floor of -$6000.0 in Q2 2021.
  • Median Non Operating Income over the past 5 years was $62000.0 (2023), compared with a mean of $137526.3.
  • Biggest five-year swings in Non Operating Income: plummeted 105.38% in 2021 and later skyrocketed 13300.0% in 2022.
  • Cyclerion Therapeutics' Non Operating Income stood at -$1000.0 in 2021, then skyrocketed by 13300.0% to $132000.0 in 2022, then decreased by 23.48% to $101000.0 in 2023, then tumbled by 72.28% to $28000.0 in 2024, then grew by 7.14% to $30000.0 in 2025.
  • The last three reported values for Non Operating Income were $30000.0 (Q3 2025), $1.3 million (Q2 2025), and $28000.0 (Q1 2025) per Business Quant data.